Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.50 |
| ▸ | RELA | Q04206 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543577 | 1.00 | ALDH1A1 (0.68) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL29410879 | 0.96 | ALDH1A1 (0.62) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL368131 | 0.96 | ALDH1A1 (0.62) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL16526953 | 0.94 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 | |
| Hydrochloric Acid SCHEMBL28389380 | 0.94 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 | |
| Sulfuric Acid SCHEMBL27798096 | 0.93 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL21168435 | 0.91 | HSD17B3 (0.55) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 | |
| Glycine SCHEMBL7128369 | 0.89 | ALDH1A1 (0.61) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 | |
| Trifluoroacetic Acid SCHEMBL8141928 | 0.88 | ALDH1A1 (0.59) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL10539670 | 0.84 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9ASMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111601790-B | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| EP-2758375-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2014-07-30 | — | — | EP | claimed |
| WO-2013042139-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-03-28 | — | — | WO | claimed |
| EP-1506196-B1 | PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2012-01-18 | — | — | EP | claimed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | claimed |
| EP-0805799-A1 | NOVEL SWEETENERS DERIVED FROM 3,4-DISUBSTITUTED $g(a)-BENZENEAMIDE N-(4-CYANOPHENYLCARBAMOYL OR 2-CYANOPYRID-5-YLCARBAMOYL)-L-ASPARTIC OR L-GLUTAMIC ACIDS | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 1997-11-12 | — | — | EP | claimed |
| WO-2024196236-A1 | NOVEL COMPOUND AS ENDOTHELIAL TO MESENCHYMAL TRANSITION (ENDMT) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-09-26 | — | — | WO | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| CN-111601790-B | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-05-05 | — | — | US | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
| EP-3613725-A1 | PRODUCTION METHOD FOR INDANE CARBOALDEHYDE | Mitsubishi Gas Chemical Company, Inc. (JP) | 2020-02-26 | — | — | EP | disclosed |
| CN-109384711-A | A kind of indane -5- formamide ROR gamma modulators and application thereof | 南京柯菲平盛辉制药有限公司 | 2019-02-26 | — | — | CN | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| EP-0004000-B2 | New propanone derivatives, process for producing thereof and pharmaceutical compositions containing these derivatives as active ingredients | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1988-06-15 | — | — | EP | disclosed |
| EP-0004000-B1 | NEW PROPANONE DERIVATIVES, PROCESS FOR PRODUCING THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES AS ACTIVE INGREDIENTS | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ALDH1A1 2571/4885NPC1 138/4885RAB9A 572/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | ALDH1A1 1335/4885NPC1 1831/4885RAB9A 2314/4885 |
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BRAF, NRAS, RAF1 | ALDH1A1 1618/4885NPC1 1038/4885RAB9A 376/4885 |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | ALDH1A1 1152/4885NPC1 3790/4885RAB9A 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.